Zhou Shan Shi

This research observes patients who have received Siltartoxatug Injection, a drug used for preventing tetanus after injuries. The study aims to document wound conditions and evaluate the clinical outcomes of tetanus prevention in a large real-world setting. It also focuses on monitoring safety by recording any side effects or serious adverse reactions from the treatment. Participants receive Siltartoxatug Injection following their injury as part of routine care. The study collects detailed information about their injury and wound status at enrollment. There is no comparison group; all participants are observed after receiving this treatment. Participants are followed for 90 days after receiving the injection. During this time, researchers assess whether tetanus develops and track any adverse events. The study uses selective safety data collection to monitor reactions to the drug. This follow-up period helps determine both the effectiveness and safety of the tetanus prevention approach using Siltartoxatug.

People with end stage kidney disease (ESKD) who require dialysis have a much higher risk of developing cardiovascular disease compared to the general population, with heart problems causing over half of the deaths in this group. This trial is studying whether taking low dose aspirin daily can safely reduce cardiovascular events in these dialysis patients. The study is a Phase 4, multi-center, randomized controlled trial designed to provide clear evidence about aspirin's benefits and risks in this specific population, where existing data is limited. Participants will be randomly assigned to receive either a daily 100 mg aspirin tablet or a matching placebo. The trial uses the Chinese peritoneal dialysis and hemodialysis registry to efficiently screen and recruit patients and collect data during routine dialysis care. Follow-up visits occur every six months as part of regular clinical care, and the study will continue until enough cardiovascular events have occurred, expected to take about five years. During the study, participants will have their health monitored through routine clinic visits every six months, with data collected on cardiovascular events and safety. The main outcome measured is the number of participants experiencing major cardiovascular events over the study period. An independent board will oversee safety and study progress. The trial uses intention-to-treat analysis and aims to minimize participant burden by integrating study procedures into usual care.

This clinical trial is a multicenter, single-blind, prospective, randomized controlled study evaluating the safety and effectiveness of combined interventions for sarcopenia in adults aged 30 and above. The study aims to compare routine care with additional supplements, including whey protein powder and eldecalcitol, while following established diagnostic criteria for sarcopenia. Participants must be able to walk and willing to complete the full treatment course. Participants are assigned to one of three groups: a control group receiving routine care with nutritional guidance, progressive resistance exercise, safety advice, and symptomatic treatment; an experimental group 1 receiving the control interventions plus whey protein powder supplementation of 60 grams daily in three doses for 12 weeks; and an experimental group 2 receiving the control care plus whey protein powder and eldecalcitol capsules at 0.75 mcg daily for 12 weeks. The total intervention lasts for 24 weeks. Throughout the study, participants undergo regular assessments including muscle mass and strength measurements, blood tests, physical function evaluations, and monitoring for adverse events. Data is collected to analyze the impact of the interventions on sarcopenia. The study also tracks liver and kidney function during protein supplementation and ensures participant safety with ongoing evaluations over the 24-week period.

Researchers are evaluating whether Bailing Capsules combined with Guben Kechuan Granules can help treat adults with stable bronchiectasis. This study aims to find out if this combination reduces the number of acute flare-ups and to assess its safety. The trial compares this combination plus standard Western medical treatment against standard Western medical treatment alone. It is a Phase 4 clinical trial focusing on patients aged 18 to 80 years with stable bronchiectasis who have experienced at least two acute exacerbations in the past year. Participants will take Bailing Capsules orally (four capsules each time, three times daily) and Guben Kechuan Granules (one bag each time, three times daily) along with standard Western treatment, or only standard Western treatment, for 24 weeks. They will visit the clinic for checkups and tests at weeks 4, 12, 24, and 48. During the study, participants will keep a diary to record their symptoms. Throughout the study, researchers will monitor the number of acute exacerbations during treatment and follow-up at 24 and 48 weeks. Participants will undergo pulmonary function tests and other evaluations during clinic visits. Safety and symptom changes will be assessed regularly, and the total observation period lasts 48 weeks. This monitoring helps understand the effects and safety of the treatment combination over time.

This trial investigates the effects of TQA2225/AP025, a recombinant human FGF21-Fc fusion protein, in adults with Non-Alcoholic Steatohepatitis (NASH). It is a randomized, double-blind, placebo-controlled Phase II study designed to evaluate the safety and effectiveness of two different doses (25mg and 50mg) of this drug compared to a placebo. Participants have a confirmed diagnosis of NASH based on liver biopsy and imaging, and the study aims to assess changes in liver health over time. Participants receive either 25mg or 50mg of TQA2225/AP025 or a matching placebo, and the treatment is administered during the study period. The trial compares the impact of these doses on liver fibrosis and inflammation, as measured by liver biopsy scores and imaging results. The study includes a treatment duration of 48 weeks, during which the drug's effect on liver tissue is closely monitored. During the study, participants undergo liver biopsies at baseline and after 48 weeks to evaluate liver changes. Additional assessments include MRI scans to measure liver fat content, laboratory tests to monitor liver enzymes and kidney function, and safety evaluations. Researchers will track participants' adherence to the treatment and monitor any side effects or changes in health status throughout the 48-week period.